ABSTRACT
INTRODUCTION

Overexpression of the recepteur d'origine nantais (RON) receptor tyrosine kinase in cancer cells
has been implicated in tumorigenic activities and malignant progression (1) (2) (3) (4) . Aberrant RON expression also has been molecularly targeted in mouse xenograph models of pancreatic ductal adenocarcinoma (PDAC) (5) (6) (7) . PDAC is a highly malignant disease with limited treatment options (8) . Studies using immunohistochemical staining have confirmed that RON is overexpressed in more than 30% of primary PDAC cases (1, 5, 6) . Aberrant RON expression also regulates PDAC cell migration, survival, and invasion through multiple signaling pathways (4) (5) (6) 9, 10) . In certain PDAC cell lines, knockdown of RON expression by specific siRNA causes PDAC cell apoptosis and increase their sensitivity in response to chemotherapeutics (4) . These preclinical studies indicate that aberrant RON signaling is critical for PDAC cell growth and survival. Moreover, aberrant RON signaling serves as a mechanism for acquired chemoresistance. However, RON expression in correlation with clinico-pathophysiological parameters has not been fully established (11) . Thus, further investigation is required to demonstrate the pathogenic role of RON in PDAC malignancy.
Targeted inhibition of RON to treat PDAC is currently under investigation (6, 7, 12, 13) . Both tyrosine kinase inhibitors (TKIs) and therapeutic monoclonal antibodies have been tested in preclinical models (7, 14) . Moreover, anti-RON antibodies have been used as a drug delivery method to improve chemotherapeutic efficacy (13) . Currently, several TKIs including PHA665752, Compound-I, and BMS-777607 that target RON signaling have been characterized in preclinical model (4) (5) (6) (14) (15) (16) . BMS-777607 is a MET superfamily inhibitor with a high specificity to RON at the enzymatic IC 50 of 1.8 nM (16) . This is the highest inhibitory IC 50 value observed among various TKIs showing RON-inhibitory activity (14) (15) (16) . The other targets of BMS-777607 include MET (IC 50 : 3.9 nM), Tyro-3 (IC 50 : 4.3), and Mer (IC 50 : 14.0 nM) (16) . ) were generated by us from L3.6pl
spheroids by sequential magnetic cell sorting methods as previously described (13) . Human MSP, mouse monoclonal antibody (mAb) Zt/g4, and rabbit polyclonal IgG antibody R5029 to RON were used as previously described (20, 21) . Mouse or rabbit IgG antibodies specific to phospho-tyrosine (clone PY-100), p85/70S6K, phospho-p85/70S6K (Thr were mixed with 1.5 μg/ml Zt/g4 coupled to protein G Sepharose beads. Proteins were separated in an 8% of SDS-PAGE under reduced conditions. Phosphorylated RON and other signaling proteins were detected by Western blotting using PY-100, R5029, and other antibodies and visualized using enhanced chemiluminescent reagents (21) . Membranes also were reprobed with rabbit IgG antibody to β-actin to ensure equal sample loading. microscope equipped with DUS/fluorescent apparatus as previously described (13) .
Assays for cell growth, viability, apoptotic death, and DNA content: Cell growth and survival was determined by the clonogenic assay (24) . L3.6pl cells in the presence or absence of BMS-777607 were cultured for 12 days to allow clonogenic growth as previously described (24) . CSCs +24/44/ESA in stem cell culture media were cultured in an ultra-low adhesion plate coated with 0.2% agarose to facilitate cell anchoring. After incubation for 18 days, clonogenic growth was determined. The effect of BMS-777607 or other chemotherapeutic agents on cell viability was determined by the MTS assay as previously described (13) . Cells were treated with but not MET expression (13) . We first determined the effect of BMS-777607 on MSP-induced RON phosphorylation, which was inhibited in a dose-dependent manner (Fig. 1A) . We then determined the effect of BMS-777607 on cell growth/survival using the clonogenic assay (24) .
BMS-777607 inhibited L3.6pl clonogenic growth in a dose-dependent manner (Fig. 1B) . More than 70% reduction in colonogenic growth was observed when BMS-777607 was used at 5 μM (Fig. 1C) . In contrast, CSCs +24/44/ESA were resistant to the inhibitory effect of 5 μM of BMS-777607. Only a slight reduction (~20%) was observed. (Fig. 2) . L3.6pl cell-derived polyploid cells were observed as early as 24h after addition of BMS-777607. However, polyploidy from CSCs +24/44/ESA were not found until 48h after BMS-777607 treatment ( Fig. 2A) . For L3.6pl cells, the minimal amount of BMS-777607 required to induce polyploidy was about 1 μM ( Fig. 2B and 2C) . At this concentration, 23% of cells were shown having polyploidy. The percentage rose when BMS-777607 was used at 5.0 μM (84%). Fig. 3B ). (Fig. 4A) . However, BMS-777607 in combination with AZD8055 or PD98059 displayed a synergistic effect on reduction of L3.6pl cell growth. The combination index is 2.0. Viable L3.6pl cells, was also reduced to 33% after BMS-777607 plus PD98059 treatment. The combination index is 1.6. Interestingly, analysis of cell apoptosis showed that BMS-777607 in combination with AZD8055 does not increase the rate of cell death (Supplementary Fig. 4) .
Thus, the viability reduction in cells treated with BMS-777607 plus AZD8055 is caused by synergistic effect that inhibits cell growth. Taken together, results in Fig. 4A suggest that BMS-777607 in combination with AZD8055 or PD98059 effectively inhibits L3.6pl cell proliferation.
We further determined the effect of combinational treatment on formation of L3.6pl polyploid cells (Fig. 4B) Fig. 4 prompted us to determine which mTOR complex (mTORC1 or mTORC2) is involved in the synergistic effect. We first determined the inhibitory effect of AZD8055 (mTOR inhibitor) (27) , RAD001 (mTORC1 inhibitor) (28) , and PP242 (dual mTORC1/ mTORC2 inhibitor) (29) on phosphorylation of their corresponding substrates (Fig. 5A) . BMS-777607 treatment had no effect on the protein expression of mTORC1 substrate p85/70S6K or mTORC2 substrate AKT. BMS-777607 also had no effect on phosphorylation of p85/79S6 Upon confirming these results, we tested the synergistic effect of AZD8055, RAD001, and PP242 with BMS-777607 on L3.6pl cell viability (Fig. 5B) . BMS-777607 was used at 1 μM, which has a slight effect on reduction of L3.6pl cell viability (<10%). Consistent with the results shown in Fig. 4 , AZD8055 in combination with BMS-777607 reduced L3.6pl cell viability in a dose-dependent manner. ADZ8055 at 0.5 μM is sufficient to synergize with BMS-777607 to achieve a 50% reduction in cell viability. In contrast, RAD001 in combination with BMS-777607 did not exert the synergistic effect on L3.6pl cell viability. However, PP242 in combination with BMS-777607 showed a significant synergism in reducing L3.6pl cell viability. Importantly, PP242 at 0.5 μM is sufficient to synergize with BMS-777607 to cause a 50% reduction in L3.6pl cell viability. We also examined the polyploidy in cells treated with different combinations.
Synergistic effect of BMS-777607 and mTOR-2 inhibitor on reduction of L3.6pl cell viability: The findings from
Percentages of polyploid cells from 1 μM BMS-777607 plus 5 μM AZD8055 or 1 μM PP242 were less than 5% in viable cells. However, the percentage of polyploid cells from BMS-777607 plus 1 μM RAD001 was about 24% in viable cells.
We also confirmed the therapeutic effect of BMS-777607 in combination with mTOR inhibitors on viability of CSCs +24/44/ESA (Fig. 6) . In this case, BMS-777607 at 5 μM is required in combination with 1 μM AZD8055 or PP242 to achieve the significant reduction of CSCs 
cell viability and polyploidy by L3.6pl cells. The mTOR pathway regulates various cellular activities, such as survival, motility, and metabolism by integrating signaling from upstream molecules including growth factors and receptor tyrosine kinases (38-40). Currently, two mTOR complexes, namely mTORC1 and mTORC2, have been identified (38-40). mTORC1 functions as a nutrient/energy/redox sensor and controls protein synthesis and mTORC2 acts primarily as a regulator of cell cycle and motility (38-40). By analyzing cell viability and polyploidy, we demonstrate that inhibition of mTOR signaling alone by AZD8055 at 1 μM is not sufficient to significantly reduce L3.6pl cell viability. However, when used in combination, BMS-777607 and AZD8055 showed a synergistic effect not only on decreased cell viability but also on reduced polyploidy. The action of AZD8055 in combination with BMS-777607 is likely to be mediated by its inhibitory effect on both mTOR1 and mTOR2. Using RAD001 and PP242 that differentially inhibit mTORC1 and mTORC2, respectively, we demonstrate that inhibition of mTORC2 but not mTORC1 has synergistic activity with BMS-777607. These results provide a mechanistic explanation of why mTOR1 inhibitor RAD001 is less effective than AZD8055 in combination with BMS-777607 to achieve the synergistic activity. RON was immunoprecipitated from cell lysates (250 μg/ml) using anti-RON mAb Zt/g4 followed by Western blot analysis using TY-100 specific to phospho-tyrosine as previously described [13] . Clonogenic growth from the cell control was set as 100%. (D) Apoptotic cell death was measured by the Annexin V-propidium iodide-labeling method (24) . Cells were treated with 5
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μM and 10 μM of BMS-777607 for three days, labeled, and then analyzed by flow cytometer as previously described [24] . Results are from one of three experiments with similar results. L3.6pl cells at 6000 cells/well were incubated in MEM with 5% FBS in triplicate in a 96-well culture plate and treated with different amounts of AZD8055, RAD001, and PP242 alone, or in combination with 1 μM BMS-777607. Cells were cultured for 72h followed by the MTS assay.
Cell viability from control cells cultured in MEM alone was set at 100%. The combination index for BMS-77607+5 μM AZD8055, BMS-777607+1 μM RAD001, and BMS-777607+PP242 is at 2.1, 1.1, and 1.6, respectively. 
